

肺癌診療指引

胸腔腫瘤暨食道癌多專科團隊

2008年09月制定

2009年05月修訂

2010年09月修訂

2011年12月修訂

2012年11月修訂

2013年07月修訂

2014年12月修訂

2015年12月修訂

參考資料：

Non-small Cell Lung Cancer NCCN Guidelines V2.2016

Small Cell Lung Cancer NCCN Guidelines V1.2016

全民健康保險藥品給付規定 行政院衛生署一百零四年版

Physicians' Cancer Chemotherapy Drug Manual 2010

☆：選項

SABR：Stereotactic ablative radiotherapy

SRS：Stereotactic radiosurgery


WBRT：Whole brain radiotherapy

SVC：Superior vena cava


Table of Contents

一、	Initial Evaluation	1
二、	Small Cell Lung Cancer Guidelines	2
三、	Lung Neuroendocrine Tumors Guidelines	7
四、	Non-Small Cell Lung Cancer Guidelines	10
五、	Chemotherapy Regimens	26
六、	Principles of Radiation Therapy	33
七、	AJCC Cancer Staging Manual 7 th (2010)	37

Initial Evaluation




Small Cell Lung Cancer




備註：轉介新光、榮總或其他醫院

Small Cell Lung Cancer



Prophylactic Cranial Irradiation (PCI) is recommended for patients with either limited-stage or extensive-stage disease who attain a complete or partial response. The recommended regimens for PCI include: 25 Gy in 10 daily fractions (2.5 Gy/fraction), 30 Gy in 10-15 daily fractions, or 24Gy in 8 daily fractions.

Small Cell Lung Cancer




Small Cell Lung Cancer

RESPONSE ASSESSMENT FOLLOWING INITIAL THERAPY

- Chest x-ray (optional)
- Chest/liver/adrenal CT with IV contrast whenever possible
- Brain MRI (preferred) or CT with IV contrast whenever possible, if prophylactic cranial irradiation (PCI) to be given
- Other imaging studies, to assess prior sites of involvement, as clinically indicated
- CBC, platelets
- Electrolytes, LFTs, Ca, BUN, creatinine

ADJUVANT TREATMENT



SURVEILLANCE

- After recovery from primary therapy:
- Oncology follow-up visits every 3–4 mo during y 1–2, every 6 mo during y 3–5, then annually
 - At every visit: H&P, chest imaging, bloodwork as clinically indicated
 - New pulmonary nodule should initiate workup for potential new primary
 - Smoking cessation intervention
 - PET 備註 /CT is not recommended for routine follow-up

→ [For Relapse, see Subsequent Therapy](#) 見 P. 6


→ [See Subsequent Therapy/Palliative Therapy](#) 見 P. 6

備註：轉介新光、榮總或其他醫院


Small Cell Lung Cancer

PROGRESSIVE DISEASE

SUBSEQUENT THERAPY/PALLIATIVE THERAPY




Lung Neuroendocrine Tumors



備註：轉介新光、榮總或其他醫院


Lung Neuroendocrine Tumors

Low-Grade Lung Neuroendocrine Carcinoma (Typical Carcinoid)




Lung Neuroendocrine Tumors


Intermediate-Grade Lung Neuroendocrine Carcinoma (Atypical Carcinoid)



Non Small Cell Lung Cancer




Non Small Cell Lung Cancer



備註：轉介新光、榮總或其他醫院

Non Small Cell Lung Cancer





Non Small Cell Lung Cancer

CLINICAL ASSESSMENT

PRETREATMENT EVALUATION

CLINICAL EVALUATION

Stage IIB (T3 invasion, N0)
Stage IIIA (T4 extension, N0-1; T3, N1)

- PFTs (if not previously done)
- Bronchoscopy
- Pathologic mediastinal lymph node evaluation
- Brain MRI with contrast
- MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine or subclavian vessels
- FDG PET 備註 /CT scan (if not previously done)

Superior sulcus tumor → [See Treatment](#) 見 P. 14

Chest wall → [See Treatment](#) 見 P. 15


Proximal airway or mediastinum → [See Treatment](#) 見 P. 15

Unresectable disease → [See Treatment](#) 見 P. 15


Metastatic disease → [See Treatment for Metastasis limited sites](#) 見 P. 22 or [distant disease](#) 見 P. 24

備註：轉介新光、榮總或其他醫院


Non Small Cell Lung Cancer



Non Small Cell Lung Cancer




Non Small Cell Lung Cancer




備註：轉介新光、榮總或其他醫院

Non Small Cell Lung Cancer




備註：轉介新光、榮總或其他醫院

Non Small Cell Lung Cancer




備註：轉介新光、榮總或其他醫院

Non Small Cell Lung Cancer




Non Small Cell Lung Cancer




備註：轉介新光、榮總或其他醫院

Non Small Cell Lung Cancer



備註：轉介新光、榮總或其他醫院

Non Small Cell Lung Cancer



備註：轉介新光、榮總或其他醫院

Non Small Cell Lung Cancer

SURVEILLANCE

- No evidence of clinical/radiographic disease, stages I-IV:
- 過去病史及身體評估 and chest CT \pm contrast every 6-12 mo for 2 y, then 過去病史及身體評估 and a low-dose non-contrast-enhanced chest CT annually
 - ▶ Patients treated with chemotherapy \pm RT who have residual abnormalities may require more frequent imaging
 - Smoking cessation advice, counseling, and pharmacotherapy
 - FDG PET/CT 備註 or brain MRI is not indicated

Locoregional recurrence


[See Therapy for Recurrence and Metastasis](#) 見 P. 24

Distant metastases

[See Therapy for Recurrence and Metastasis](#) 見 P. 24


備註：轉介新光、榮總或其他醫院

Non Small Cell Lung Cancer





Non Small Cell Lung Cancer



Non Small Cell Lung Cancer

Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling

Stage IA		Stage IB	Stage IIA		Stage IIA	Stage IIB		Stage IIIA
T1ab, N0		T2a, N0	T2b, N0		T1ab-T2a, N1	T3, N0; T2b, N1		T1-3, N2; T3 [>7 cm], N1
Margins(-) R0	Margins(+) R1.R2	Margins(-) R0	Margins(+) R1.R2		Margins(-) R0	Margins(+) R1.R2		Margins(-) R0 Margins(+) R1.R2 or nodal ECE
Observe	Reresection(preferred) or RT	Observe	Reresection(preferred) ± C/T or RT±C/T (C/T for stage IIA)		C/T	Reresection + C/T or CCRT+C/T		C/T or RT(N2 only) CCRT+C/T

CHEMOTHERAPY REGIMENS FOR NEOADJUVANT AND ADJUVANT THERAPY

(Non-Small Cell Carcinoma)

- Cisplatin 50 mg/m² days 1 and 8; vinorelbine 25 mg/m² days 1, 8, 15, 22, every 28 days for 4 cycles*
- Cisplatin 75 mg/m² on day 1; gemcitabine 1250 mg/m² on days 1, 8 every 21 days for 4 cycles *
- Cisplatin 75 mg/m²; docetaxel 75 mg/m² every 21 days for 4 cycles *

Chemotherapy Regimens for patients with comorbidities or patients not able to tolerate cisplatin Paclitaxel 200 mg/m² on day 1, carboplatin AUC 6 on day 1, every 21 days*

*These regimens can be used as neoadjuvant chemotherapy. They are to be given for 3 cycles prior to localized therapy. See Discussion for further information and references.

References

1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-lung cancer. N Engl J Med 2005;352:2589-2597.
2. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21(16):3016-24. Epub 2003 Jul 1.
3. Strauss GM, Herndon III JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-5051.

CHEMOTHERAPY REGIMENS USED WITH RADIATION THERAPY (Non-small cell carcinoma)**Concurrent Chemotherapy/RT Regimens**

- Cisplatin 50 mg/m² on day 1, 8, 29, and 36; etoposide 50 mg/m² days 1-5, 29-33; concurrent thoracic RT (preferred)**
- Cisplatin 75mg/m² on day1, Pemetrexed 500mg/m² on day 1 every 21 days for 4 cycles; concurrent thoracic RT (nonsquamous) (Option)
- Carboplatin AUC 5 on day1, Pemetrexed 500mg/m² on day 1 every 21 days for 4 cycles; concurrent thoracic RT (nonsquamous) (Option)

*There are data that support full-dose cisplatin over carboplatin-based regimens. Carboplatin regimens have not been adequately tested.

**These regimens can be used as neoadjuvant chemoradiotherapy. Cisplatin and etoposide is the preferred regimen. If weekly carboplatin and paclitaxel is used because the patient is not able to tolerate concurrent full-dose cisplatin and radiotherapy, the treating physician should consider 3 cycles of full-dose platinum therapy after local treatment is completed.

References

- Albain KS, Crowley JJ, Turrisi AT III, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019. J Clin Oncol 2002;20:3454-3460.
- Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452-1460.
- Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer; Cancer and leukemia Group B trial 30407. J Clin Oncol 2011;29:3120-3125.
- Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009;10:193-198

非小細胞肺癌健保化療藥物適用細胞型態一覽表

	Adenocarcinoma	Squamous Cell Ca	Adjuvant C/T
Taxotere (Docetaxel)	V	V	
Gemzar	V	V	
Paclitaxel (Taxol)	V (+ cis)	V	
Vinorelbine	V	V	V (+cis x 4 courses)
U-Fur	V	V	V (T2,>3cm x 2yrs)
Alimta	<u>V</u>		
Iressa (Gefitinib)	<u>V</u>		
Tarceva (Erlotinib)	<u>V</u>	<u>V (第三線)</u>	
Afatinib(Giotrif)	<u>V</u>		
Crizotinib(Xalkori)	<u>V</u>		

(底線部分需事先申請) 健保給付規定可見 P.42-45

CHEMOTHERAPY REGIMENS FOR ADJUVANT THERAPY (Small cell carcinoma)**Limited stage (maximum of 4-6 cycles)**

- Cisplatin 60 mg/m² day 1 and etoposide 120 mg/m² days 1, 2, 3
- Cisplatin 80 mg/m² day 1 and etoposide 100 mg/m² days 1, 2, 3
- Carboplatin AUC 5-6 day 1 and etoposide 100 mg/m² days 1, 2, 3
- During chemotherapy + RT, cisplatin/etoposide is recommended
- The use of myeloid growth factors is not recommended during concurrent chemotherapy plus radiotherapy.

Extensive stage (maximum of 4-6 cycles)

- Cisplatin 75 mg/m² day 1 and etoposide 100 mg/m² days 1, 2, 3
- Cisplatin 80 mg/m² day 1 and etoposide 80 mg/m² days 1, 2, 3
- Cisplatin 25 mg/m² days 1, 2, 3 and etoposide 100 mg/m² days 1, 2, 3
- Carboplatin AUC 5-6 day 1 and etoposide 100 mg/m² days 1, 2, 3
- Cisplatin 60 mg/m² day 1 and irinotecan 60 mg/m² days 1, 8, 15
- Cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1, 8
- Carboplatin AUC 5 day 1 and Irinotecan 50 mg/m² days 1, 8, and 15

Subsequent chemotherapy:

- Clinical trial preferred.
- Relapse < 2-3 mo, PS 0-2 : paclitaxel、docetaxel、topotecan PO or IV、irinotecan、temozolomide 75mg/m²/day x 21 days、ifosfamide、gemcitabine
- Relapse > 2-3 mo up to 6 mo topotecan : PO or IV (category 1)、paclitaxel、docetaxel、irinotecan、gemcitabine、vinorelbine、oral etoposide、temozolomide mg/m² day x 21 days 75cyclophosphamide/doxorubicin/vincristine (CAV)
- Relapse > 6 mo : original regimen

Consider dose reductions versus growth factors in the poor performance status patient.

References

- ¹ Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med* 1999;340(4):265-271.
- ² Saito H, Takada Y, Ichinose Y, et al. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. *J Clin Oncol* 2006;24(33): 5247-5252.
- ³ Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). *Ann Oncol* 2001;12(9):1231-1238.
- ⁴ Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years follow-up. *J Clin Oncol* 2002;20(24):4665-4672.
- ⁵ Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high- dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. *J Clin Oncol* 1994;12(10):2022-2034.
- ⁶ Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. *J Clin Oncol* 1985;3(11):1471-1477.
- ⁷ Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma- concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer. *J Clin Oncol* 1999;17(11):3540- 3545.
- ⁸ Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell

lung cancer. *N Engl J Med* 2002;346(2): 85-91.

- ⁹ Hanna N, Bunn Jr. PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol* 2006;24(13):2038-2043.
- ¹⁰ Schmittel A, Fischer von Weikersthal L, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. *Ann Oncol* 2006;17:663-667.
- ¹¹ Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. *Br J Cancer* 1998; 77:347-351.
- ¹² Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. *Anticancer Res* 2006; 26:777-781.
- ¹³ Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. *Eur J Cancer* 1994; 30A:1058-1060.
- ¹⁴ von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol* 1999;17(2):658-667.
- ¹⁵ O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. *J Clin Oncol* 2006;24(34):5441-5447.
- ¹⁶ Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. *J Clin Oncol* 1992; 10:1225-1229.
- ¹⁷ Cantwell BM, Bozzino JM, Corris P, et al. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. *Eur J Cancer Clin Oncol* 1988; 24:123-129.
- ¹⁸ Van der Lee I, Smit EF, van Putten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. *An*

-
- Oncol 2001; 12:557-561.
- 19 Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer. J Clin Oncol 2003; 21:1550-1555.
- 20 Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25(15):2086-2092.
- 21 Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 1993; 29A:1720-1722.
- 22 Furuse K, Kuboa K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 1996; 53:169-172.
- 23 Einhorn LH, Pennington K, McClean J. Phase II trial of daily oral VP-16 in refractory small cell lung cancer. Semin Oncol 1990; 17:32-35.
- 24 Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990; 8:1613-1617.
- 25 Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987;23:1409-1411.
- 26 Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987;23:1697-1699.

肺癌放射線治療政策

Non-Small Cell Lung Cancer

I-II Operable: Adjuvant RT is not indicated except for + margin (PORT meta-analysis Level I)

I-II Inoperable:

Definitive RT .

C/T, if patient can tolerate, maybe added as induction, adjuvant , or concurrent.

IIIA Operable

Post-OP C/T , (+, -) RT indicated for close/+ margin, nodal ECE (SEER, Level IV)

Alternatively, neoadjuvant CCRT followed by re-staging and surgery (SWOG 8805, Level III). Pre-OP RT alone is not recommended for resectable disease (GradeA)

III Inoperable

Combined C/T and RT(prefer)

Radiation Technique

- **Adjuvant**

CTV: Involved LN region \pm ipsilateral hilum \pm subcarinal LN region to 50.4 Gy depending on the extent of node dissection, number, bulk, and location of mediastinal disease and primary tumor. 10–16 Gy boost if extranodal extension with gross residual disease, at least 66Gy, concurrent C/T should be considered (Level II)

- **Definitive Radiation**

At least 66GY with conventional fractionation, concurrent C/T should be considered

GTV is visible tumor on imaging including all nodes on CT \geq 1 cm, or PET/CT (+)

CTV is the region of microscopic disease spread. It expands the GTV by 10-15 mm

PTV: add 0.5–1.5 cm margin on CTV to account for set-up uncertainties and respiratory motion.

IMRT may be advantageous as it better limits dose to normal lung as compared to conventional delivery.

Small Cell Lung Cancer

- **Limited Stage**

ECOG 0-2 CCRT (prefer)

Prophylactic Cranial Irradiation (PCI) is part of the standard treatment for SCLC with complete response after treatment (Grade A)

PCI is also recommended for SCLC with partial response after treatment. (Grade B)

- **Extensive Stage**

Chemotherapy is the mainstay treatment of extensive stage SCLC (Grade A)

Radiotherapy is usually reserved for palliation.

PCI should be considered in all SCLC patients who achieve response to C/T (Grade A, EORTC, Level I)

- **Radiation Technique**

GTV is visible tumor on imaging including all nodes on CT \geq 1 cm, or PET/CT (+)

CTV is the region of microscopic disease spread. It expands the GTV by 10-15 mm

PTV: add 0.5–1.0cm margin on CTV to account for set-up uncertainties and respiratory motion.

Dose: With conventional fractionation, 54Gy or higher should be considered (Grade B)

執行程序(procedures)

Simulation for Lung Cancer

Immobilize with a with customized immobilization device (with arms up). 4D planning is preferred.

Dose Limiting Structures

Spinal Cord:

Dose of radiation to the spinal cord should be limited to 45 Gy (1.8–2.0 Gy daily) (Level I)

Esophagus: Dose to the esophagus should be limited to 60 Gy for 1/3 of the esophagus, or 55 Gy for the 2/3 of the esophagus. 45Gy for the entire esophagus

Heart: V40 of the heart should be limited to 50% or less.

Lung: V20 of bilateral lung should be limited to $\leq 30\%$ as probability of pneumonitis increases rapidly when more than V20 $> 30\%$ (Level III).

References

1. Decision Making in Radiation Oncology, V1-2, L.W. Brady, H.-P. et al, 2011
2. Handbook of Evidence-Based Radiation Oncology, Eric K. Hansen et al, 2010

PRIMARY TUMOR (T)	
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Tis Carcinoma in situ
T1	Tumor ≤ 3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)*
T1a	Tumor ≤ 2 cm in greatest dimension
T1b	Tumor > 2 cm but ≤ 3 cm in greatest dimension
T2	Tumor > 3 cm but ≤ 7 cm or tumor with any of the following features (T2 tumors with these features are classified T2a if ≤ 5 cm) Involves main bronchus, ≥ 2 cm distal to the carina Invades visceral pleura (PL1 or PL2) Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung
T2a	Tumor > 3 cm but ≤ 5 cm in greatest dimension
T2b	Tumor > 5 cm but ≤ 7 cm in greatest dimension
T3	Tumor > 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (< 2 cm distal to the carina* but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe
T4	Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, separate tumor nodule(s) in a different ipsilateral lobe
* The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus, is also classified as T1a.	

REGIONAL LYMPH NODES (N)	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension
N2	Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3	Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)

DISTANT METASTASIS (M)	
M0	No distant metastasis (no pathologic M0; use clinical M to complete stage group)
M1	Distant metastasis
M1a	Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion**
M1b	Distant metastasis
<p>**Most pleural (and pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple cytopathologic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and is not an exudate. Where these elements and clinical judgement dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element and the patient should be classified as M0.</p>	

STAGE			
GROUP	T	N	M
Occult	TX	N0	M0
0	Tis	N0	M0
IA	T1a	N0	M0
	T1b	N0	M0
IB	T2a	N0	M0
IIA	T2b	N0	M0
	T1a	N1	M0
	T1b	N1	M0
	T2a	N1	M0
IIB	T2b	N1	M0
	T3	N0	M0
IIIA	T1a	N2	M0
	T1b	N2	M0
	T2a	N2	M0
	T2b	N2	M0
	T3	N1	M0
	T3	N2	M0
	T4	N0	M0
	T4	N1	M0

`STAGE			
GROUP	T	N	M
IIIB	T1a	N3	M0
	T2b	N3	M0
	T2a	N3	M0
	T2b	N3	M0
	T3	N3	M0
	T4	N2	M0
IV	Any T	Any N	M1a
	Any T	Any N	M1b
Stage unknown			

9.9. Vinorelbine：(91/1/1、95/6/1、96/9/1、101/3/1)

1. 限用於：

- (1) 晚期或無法手術切除之非小細胞肺癌及轉移性乳癌病患。
- (2) 病理分期第二期及第三期前半(stage II & stage IIIA)非小細胞肺癌於接受根治性手術後與鉑金類藥品併用之輔助治療，需事前審查後使用，最長以4療程為限。

2. 本成分之口服劑型與注射劑型不得併用。

9.11. Uracil-Tegafur (如 Ufur)：(100/1/1)

3. 與 cisplatin 併用治療轉移及末期肺癌。

5. 用於病理分期為 T2 且腫瘤 \geq 3cm 之肺腺癌病人，作為手術後輔助治療，使用期限以二年為限。(100/1/1)

9.24. Gefitinib (如 Iressa):(93/11/1、96/8/1、96/11/1、100/6/1、101/5/1、101/10/1、103/5/1)

1. 限單獨使用於

- (1) 具有 EGFR-TK 基因突變之局部侵犯性或轉移性(即第ⅢB期或第Ⅳ期)之肺腺癌病患之第一線治療。
(100/6/1)

- (2) 先前已使用過第一線含鉑化學治療，或70歲(含)以上接受過第一線化學治療，但仍局部惡化或轉移之肺腺癌。(96/11/1、100/6/1)

2. 需經事前審查核准後使用：

- (1) 用於第一線用藥：檢具確實患有肺腺癌之病理或細胞檢查報告，及 EGFR-TK 基因突變檢測報告。(100/6/1)
- (2) 用於第二線以上用藥：檢具確實患有肺腺癌之病理或細胞檢查報告，並附曾經接受第一線含鉑化學治療，或70歲(含)以上接受過第一線化學治療之證明，及目前又有疾病惡化之影像診斷證明(如胸部X光、電腦斷層或其他可作為評估的影像)，此影像證明以可測量(measurable)的病灶為優先，如沒有可以測量的病灶，則可評估(evaluable)的病灶亦可採用。(96/11/1、100/6/1)

- (3) 每次申請事前審查之療程以三個月為限，每三個月需再次申請，再次申請時並需附上治療後相關臨床資料，如給藥四週後，需追蹤胸部 X 光或電腦斷層等影像檢查一遍，評估療效，往後每四週做胸部 X 光檢查，每隔八週需追蹤其作為評估藥效的影像（如胸部 X 光或電腦斷層）(101/5/1)。
3. 醫師每次開藥以 4 週為限。
4. 本藥品與 erlotinib(如 Tarceva)及 afatinib(如 Giotrif)不得併用。(96/8/1、103/5/1)

9.29. Erlotinib (如 Tarceva) : (96/6/1、96/8/1、97/6/1、101/5/1、102/4/1、103/5/1)

1. 限單獨使用於

- (1) 已接受 4 個週期 platinum 類第一線化學療法後，腫瘤範圍穩定(stable disease，不含 partial response 或 complete response)之局部晚期或轉移性肺腺癌的維持療法。(102/4/1)
- (2) 先前已使用過 platinum 類第一線化學治療，或 70 歲(含)以上接受過第一線化學治療，但仍局部惡化或轉移之腺性非小細胞肺癌之第二線用藥。(97/6/1)
- (3) 先前已使用過 platinum 類及 docetaxel 或 paclitaxel 化學治療後，但仍局部惡化或轉移之非小細胞肺癌之第三線用藥。

2. 需經事前審查核准後使用，若經事前審查核准，因臨床治療需轉換同成份不同含量品項，得經報備後依臨床狀況轉換使用，惟總使用期限不得超過該次申請事前審查之療程期限。(97/6/1)

- (1) 用於已接受 platinum 類第一線化學療法後，病情穩定之維持療法：檢具確實患有肺腺癌之病理或細胞檢查報告，並附已接受 4 個週期 platinum 類第一線化學療法後，腫瘤範圍穩定(stable disease，不含 partial response 或 complete response)之影像診斷證明（如胸部 X 光、電腦斷層或其他可作為評估的影像）。(102/4/1)
- (2) 用於第二線用藥：檢具確實患有非小細胞肺癌之病理或細胞檢查報告，並附曾經接受 platinum 類第一線化學治療，或 70 歲(含)以上接受過第一線化學治療之證明，及目前又有疾病惡化之影像診斷證明（如胸部 X 光、電腦斷層或其他可作為評估的影像），此影像證明以可測量 (measurable) 的病灶為優先，如沒有可

以測量的病灶，則可評估 (evaluable) 的病灶亦可採用。(97/6/1)

- (3) 用於第三線用藥：檢具確實患有非小細胞肺癌之病理或細胞檢查報告，並附曾經接受第一線及第二線化學藥物如 platinum (cisplatin 或 carboplatin) 與 taxanes (paclitaxel 或 docetaxel) 治療之證明，及目前又有疾病惡化之影像診斷證明 (如胸部 X 光、電腦斷層或其他可作為評估的影像)，此影像證明以可測量 (measurable) 的病灶為優先，如沒有可以測量的病灶，則可評估 (evaluable) 的病灶亦可採用。(97/6/1)
- (4) 每次申請事前審查之療程以三個月為限，每三個月需再次申請，再次申請時並需附上治療後相關臨床資料，如給藥四週後，需追蹤胸部 X 光或電腦斷層等影像檢查一遍，評估療效，往後每四週做胸部 X 光檢查，每隔八週需追蹤其作為評估藥效的影像 (如胸部 X 光或電腦斷層)。(101/5/1)

3. 醫師每次開藥以 4 週為限。

4. 本藥品與 gefitinib(如 Iressa)及 afatinib(如 Giotrif)不得併用。(96/8/1、103/5/1)

9.45. Afatinib (如 Giotrif): (103/5/1)

1. 限單獨使用於具有 EGFR-TK 基因突變之局部晚期或轉移性(即第 III B 期或第 IV 期)之肺腺癌病患之第一線治療。
2. 需經事前審查核准後使用，若經事前審查核准，因臨床治療需轉換同成分不同含量品項，得經報備後依臨床狀況轉換使用，惟總使用期限不得超過該次申請事前審查之療程期限。
 - (1) 檢具確實患有肺腺癌之病理或細胞檢查報告，及 EGFR-TK 基因突變檢測報告。
 - (2) 每次申請事前審查之療程以三個月為限，每三個月需再次申請，再次申請時並需附上治療後相關臨床資料，如給藥四週後，需追蹤胸部 X 光或電腦斷層等影像檢查一遍，評估療效，往後每四週做胸部 X 光檢查，每隔八週需追蹤其作為評估藥效的影像 (如胸部 X 光或電腦斷層)
3. 使用本藥品後，除因耐受性不良，否則不得轉換類似藥理機轉之其他酪胺酸激酶阻斷劑 (tyrosine kinase inhibitor, TKI)。
4. 醫師每次開藥以 4 週為限。

5. 本藥品與 gefitinib (如 Iressa) 及 erlotinib(如 Tarceva)不得併用。

9.50. Crizotinib (如 Xalkori) : (104/9/1)

1. 適用於已接受一種含 platinum 類第一線化學治療失敗之 ALK 陽性之晚期非小細胞肺癌患者(健保第二線),(或自費可第一線使用)。
2. 符合前述之病患且併有腦轉移之非小細胞肺癌病人, 需達腦部穩定狀態(brain stabilized)始得使用。腦部穩定狀態定義為「無因腦轉移之臨床症狀(Asymptomatic brain metastases)或有腦轉移之臨床症狀(Symptomatic brain metastases)經治療後腦轉移相關臨床症狀穩定至少達三週以上之病人(類固醇劑量穩定)」。
3. 須經事前審查核准後使用:
 - (1) 需檢具確實患有非小細胞肺癌之病理或細胞檢查報告, 並附曾經接受第一線含鉑化學治療又有疾病惡化之影像診斷證明(如胸部 X 光、電腦斷層或其他可作為評估的影像), 此影像證明以可測量 (measurable) 的病灶為優先, 如沒有可以測量的病灶, 則可評估 (evaluatable) 的病灶亦可採用。
 - (2) 每次申請事前審查之療程以三個月為限, 每三個月需再次申請, 再次申請時並需附上治療後相關臨床資料, 如給藥四週後, 需追蹤胸部 X 光或電腦斷層等影像檢查一遍, 評估療效, 往後每四週做胸部 X 光檢查, 每隔八週需追蹤其作為評估藥效的影像(如胸部 X 光或電腦斷層)。
 - (3) 每次處方以 4 週為限。